Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | XPO1 | O14980 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10276944 | 0.87 | S1PR1 (0.42) | DGAT1HDAC1HDAC6S1PR1MAPT | |
| SCHEMBL10276518 | 0.86 | DGAT1 (0.41) | DGAT1HDAC1HDAC6S1PR1 | |
| SCHEMBL30722053 | 0.86 | DGAT1 (0.41) | DGAT1HDAC1HDAC6S1PR1 | |
| SCHEMBL3508159 | 0.82 | DGAT1 (0.40) | DGAT1HDAC1HDAC6KDM4EMAPT | |
| SCHEMBL1785976 | 0.82 | DGAT1 (0.39) | DGAT1HDAC1HDAC6XPO1KDM4E | |
| SCHEMBL10276731 | 0.80 | DGAT1 (0.45) | DGAT1KDM4E | |
| SCHEMBL1442690 | 0.79 | — | — | |
| SCHEMBL30726006 | 0.76 | HDAC1 (0.46) | DGAT1HDAC1HDAC6S1PR1KDM4E | |
| SCHEMBL30503765 | 0.74 | DGAT1 (0.42) | DGAT1HDAC1HDAC6XPO1 | |
| SCHEMBL1441262 | 0.74 | DGAT1 (0.45) | DGAT1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865726-B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | ARRAY BIOPHARMA INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2011029027-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178715-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, EIF4EBP1 | DGAT1 4722/4885HDAC1 578/4885HDAC6 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.